LLY

CNBC's Investing Club released its daily "Homestretch" afternoon update, highlighting Eli Lilly making a new investment or acquisition move and notable insider buying activity at Broadcom. The article is a recurring daily recap segment rather than a deep-dive on either company. Specific deal terms or insider transaction sizes are not detailed in the available text.

Eli Lilly has announced the acquisition of 4E Therapeutics, a developer focused on pain therapies. The deal expands Lilly's pipeline in the pain management space. Financial terms of the transaction were not disclosed in the article.

Eli Lilly announced plans to acquire three privately held vaccine manufacturers in deals totaling nearly $4 billion combined, marking a significant push into the vaccine space. The acquisitions represent a strategic expansion beyond Lilly's core therapeutic areas. The target companies are privately held, so no additional public tickers are directly implicated.

Eli Lilly is planning nearly $4 billion in vaccine-related deals as part of a strategic expansion into infectious disease research and development. The news sent LLY shares modestly higher. No specific deal counterparties or timelines were disclosed in the report.

Eli Lilly announced plans to acquire three vaccine development companies in deals valued at up to $4 billion in total. The transactions represent a significant expansion of Lilly's presence in the vaccine space. No further details on the individual deal structures or target company names were provided in the article.

Eli Lilly has announced a confirmed acquisition of Curevo, a company focused on next-generation shingles prevention. The deal is aimed at advancing Curevo's pipeline in the shingles vaccine/prevention space. No financial terms were disclosed in the headline.

Eli Lilly has agreed to acquire Engage Bio in a deal valued at up to $202 million, targeting the non-viral genetic medicines space. The transaction expands Lilly's pipeline in gene therapy delivery technologies that do not rely on viral vectors. Financial terms include milestone-based payments that could bring the total consideration to $202 million.

Eli Lilly has acquired Engage Biologics Inc., a preclinical biotechnology company developing the Tethosome non-viral DNA delivery platform, which combines engineered DNA payloads with lipid nanoparticle delivery. The platform is designed to address limitations in DNA delivery including potency, tolerability, and redosability. Financial terms of the acquisition were not disclosed in the announcement.

CNBC's Investing Club "Homestretch" afternoon update highlights new data supporting Eli Lilly's obesity pill and Google's new AI features. The piece is a recurring daily newsletter segment rather than a standalone news report. No specific clinical trial results, financial figures, or product details are provided in the excerpt.

CNBC's Investing Club published its routine "Homestretch" afternoon update referencing Eli Lilly's intraday price volatility following a post-earnings surge the prior week. The article is a recurring daily newsletter segment rather than a standalone news report with new fundamental disclosures. No specific financial data, guidance changes, or catalysts are detailed in the body.

A SeekingAlpha roundup article highlights key deals of the week involving Organon, ARC Resources, Nebius, and Eli Lilly among others. The article is a curated recap of multiple transactions across different companies and sectors. No single new deal is broken or confirmed within the article itself.

CNBC's Jim Cramer, via the Investing Club Morning Meeting, expressed continued bullishness on Apple and Eli Lilly following their recent post-earnings price rallies. The commentary suggests both stocks have further upside potential, though no new fundamental data or catalysts were presented. This is opinion-based commentary from a media personality rather than a new corporate or analyst development.

CNBC's Investing Club "Homestretch" segment covers the amended Microsoft-OpenAI deal and mixed news for Eli Lilly. The article is a brief afternoon trading update newsletter with no detailed disclosures on the Microsoft-OpenAI restructuring or specifics on Eli Lilly's news. No substantive new information is provided beyond the headline references.

Hims & Hers Health has expanded its platform to allow clinicians to prescribe Eli Lilly GLP-1 treatments (Zepbound vials, KwikPen, and Foundayo) fulfilled via LillyDirect, while also broadening access to Novo Nordisk therapies. The company additionally acquired a facility to strengthen peptide capabilities ahead of an FDA review on compounding. These moves deepen HIMS's role in prescription weight management and could materially shift its product mix.

Eli Lilly's new oral GLP-1 weight-loss drug is reportedly seeing prescription volumes trail Novo Nordisk's oral Wegovy. JPMorgan has initiated coverage on Hims & Hers Health. Regeneron is offering a new hearing-loss therapy at no cost.

Spherix Global Insights released a report finding high adoption rates among physicians for both Eli Lilly's LillyDirect and Novo Nordisk's NovoCare direct-to-patient platforms for obesity treatment, though workflow differences are driving a specialty-based split in platform preference. LillyDirect launched in January 2024 and NovoCare in March 2025, with both now increasingly integrated into physician workflows. The report highlights evolving competitive dynamics in the direct-to-patient obesity drug distribution channel.

Eli Lilly's stock declined after data showed Novo Nordisk's oral Wegovy outperforming Lilly's newly launched weight-loss pill, Foundayo. The comparison highlights intensifying competition in the oral GLP-1 weight-loss drug market. Both companies are vying for market share in the rapidly growing obesity treatment segment.

Eli Lilly shares fell approximately 2% following the release of mixed weekly prescription data for its GLP-1 drug portfolio. IQVIA data cited by Morgan Stanley showed Mounjaro total prescriptions rose to ~758,400 for the week ending April 17, 2026, up from ~749,500 the prior week, with new prescriptions also ticking higher to ~367,900. Despite the sequential growth in Mounjaro volumes, the broader mixed trends across the GLP-1 portfolio weighed on the stock.

Eli Lilly's new oral weight-loss drug Foundayo is showing slow early prescription uptake, according to new prescription data. The sluggish start highlights the challenge Lilly faces in competing with Novo Nordisk in the obesity drug market. The data represents an early indicator only and does not reflect long-term commercial trajectory.

CNBC highlights stocks with the largest midday price moves, including Intel, AMD, Charter, Hims & Hers, and Eli Lilly, among others. The article serves as a market roundup without providing specific details on the direction or magnitude of each move. No individual company news or catalysts are elaborated upon in the available text.

Eli Lilly shares fell as its obesity drug Foundayo showed a weaker early commercial trajectory compared to oral Wegovy, while Novo Nordisk shares climbed on the contrast. Regeneron announced a drug pricing deal, and two unspecified companies disclosed leadership changes. The FDA also announced plans to issue vouchers related to psychedelic treatments.

Hims & Hers Health is pivoting away from GLP-1 compounding, announcing it will allow providers to prescribe scripts filled through LillyDirect, Eli Lilly's direct-to-consumer platform. The move marks a strategic retreat from compounded GLP-1 drugs, which had been a key growth driver for the company. The stock is falling on the news, as the so-called "Netflix" argument — that Hims could build a subscription-based weight-loss platform — loses credibility.

Hims & Hers Health announced it will allow providers on its platform to prescribe medications fulfilled through LillyDirect, Eli Lilly's direct-to-consumer pharmacy service. The deal signals a shift in Hims & Hers' business model toward partnering with branded drug manufacturers rather than competing solely on compounded or generic alternatives. Hims stock dropped on the news, likely reflecting concerns about margin pressure or competitive dynamics.

The Motley Fool publishes a promotional piece advocating for the Vanguard S&P 500 ETF (VOO) as a long-term, low-cost investment vehicle. The article highlights the S&P 500's historical resilience across market crises and its index reconstitution mechanism as key advantages over active trading. Several S&P 500 constituent stocks — including AMZN, GOOG/GOOGL, MSFT, V, MA, LLY, and PLTR — are cited as examples of the index's holdings.